Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastien J Hotte

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
BJUI Compass|August 11, 2022
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based studyShawn Malone, Christopher J D Wallis, Richard Lee-Ying, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinomaGuru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate CancerEric Winquist, Sebastien J Hotte, Kim Chi, et al.
Clinical Genitourinary Cancer|May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 8, 2018
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trialsPierre I Karakiewicz, Emanuele Zaffuto, Anil Kapoor, et al.
International Journal of Cancer|September 6, 2012
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trialBen Tran, Andrew M K Brown, Philippe L Bedard, et al.
Future Oncology (London, England)|June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirMichael Ong, Christopher Morash, Robert J Hamilton, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
BJUI Compass|August 11, 2022
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based studyShawn Malone, Christopher J D Wallis, Richard Lee-Ying, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinomaGuru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate CancerEric Winquist, Sebastien J Hotte, Kim Chi, et al.
Clinical Genitourinary Cancer|May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 8, 2018
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trialsPierre I Karakiewicz, Emanuele Zaffuto, Anil Kapoor, et al.
International Journal of Cancer|September 6, 2012
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trialBen Tran, Andrew M K Brown, Philippe L Bedard, et al.
Future Oncology (London, England)|June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirMichael Ong, Christopher Morash, Robert J Hamilton, et al.
Pageof 9